Filing Details

Accession Number:
0001209191-13-044777
Form Type:
4
Zero Holdings:
No
Publication Time:
2013-09-18 18:37:15
Reporting Period:
2013-09-16
Filing Date:
2013-09-18
Accepted Time:
2013-09-18 18:37:15
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1427925 Acelrx Pharmaceuticals Inc ACRX Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1198330 P Guy Nohra One Embarcadero Center
37Th Floor
San Francisco CA 94111
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2013-09-16 16,398 $10.75 2,778,509 No 4 S Indirect ACP IV, L.P.
Common Stock Disposition 2013-09-17 49,921 $10.48 2,728,588 No 4 S Indirect ACP IV, L.P.
Common Stock Disposition 2013-09-18 62,461 $10.29 2,666,127 No 4 S Indirect ACP IV, L.P.
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect ACP IV, L.P.
No 4 S Indirect ACP IV, L.P.
No 4 S Indirect ACP IV, L.P.
Footnotes
  1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 6, 2013.
  2. The price reported in Column 4 is a weighted average price. The range of sale prices for the transactions reported was $10.56 to $10.87 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
  3. The shares are owned by ACP IV, L.P. ("ACPIV"). ACMP IV, LLC (the "General Partner") serves as the general partner of ACPIV, L.P. and possesses power to direct the voting and disposition of the shares owned by ACPIV and may be deemed to have indirect beneficial ownership of the shares held by ACPIV. The General Partner owns no securities of the Issuer directly. The Reporting Person is a member of the General Partner. As such, the Reporting Person shares voting and investment power over the shares held by ACPIV. The Reporting Person disclaims beneficial ownership of the shares held by ACP IV except to the extent of his proportionate pecuniary interest therein.
  4. The price reported in Column 4 is a weighted average price. The range of sale prices for the transactions reported was $10.41 to $10.70 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
  5. The price reported in Column 4 is a weighted average price. The range of sale prices for the transactions reported was $10.24 to $10.44 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.